Michelle Mitchell, Chief Executive at Cancer Research UK, shared on LinkedIn:
“For too many people diagnosed with pancreatic cancer, progress has felt painfully slow.
Pancreatic cancer remains one of the most challenging cancers to treat, and survival rates are still far too low. That’s why it’s so encouraging to see the results from this new clinical trial. While further research is needed, findings like these offer hope that we may be starting to see new possibilities emerge for people affected by this devastating disease.
Research is helping us understand pancreatic cancer better than ever before, opening the door to new approaches that weren’t possible a generation ago.
For families facing pancreatic cancer today, advances like these could eventually mean more treatment options, more time and better outcomes. But progress doesn’t happen by chance. It comes from years of dedication by researchers, clinicians, patients and supporters who believe we can do better.
At Cancer Research UK, we’re committed to accelerating progress against hard-to-treat cancers like pancreatic cancer. Earlier this year we brought together researchers, clinicians and partners at our first Pancreatic Cancer Conference because collaboration will be critical if we’re going to improve survival and outcomes faster. There is real reason for optimism. But there is also an urgent need to keep investing in research so that discoveries like this become routine rather than remarkable.
Every breakthrough brings us closer to a world where more people live longer, better lives, free from the fear of cancer.”
To which, Samra Turajlić, Director of the Cancer Research UK Manchester Institute, Consultant Oncologist at The Christie and Professor at the University of Manchester, added:
“It was fantastic to have these data presented at the 38th ENA 2026 Symposium – the results are profound- scientifically and clinically!
I agree wholeheartedly with Michelle Mitchell that this places even greater pressure on the PDAC scientist and clinicians to work closely together to support further progress – from understanding PDAC initiation, to metastasis to therapy. We are deeply committed to exactly this kind of collaborative work in Manchester!”
Find out more:
The European Commission Approves Revolution Medicines’ Daraxonrasib for Metastatic Pancreatic Cancer
